Prevalence at enrollment and incidence rates of cervical HPV infection by genotype and number of coinfections
| Genotype . | Prevalence at entry, n (%)* . | Woman-months of follow-up† . | All incident infections . | . | No coinfection‡ . | . | One or more coinfection‡ . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | No. incident infections§ . | Incidence rate per 1,000 woman-months (95% CI) . | No. incident infections∥ . | Incidence rate per 1,000 woman-months (95% CI) . | No. incident infections¶ . | Incidence rate per 1,000 woman-months (95% CI) . | ||||||||
| Any HPV** | 603 (25.6) | 9075 | 118 | 13.00 (10.76–15.57) | ||||||||||||
| HR-HPV†† | 493 (20.9) | 10150 | 94 | 9.26 (7.48–11.33) | 45 | 4.43 (3.23–5.93) | 49 | 4.83 (3.57–6.38) | ||||||||
| 16 | 110 (4.7) | 13596 | 24 | 1.77 (1.13–2.63) | 3 | 0.22 (0.05–0.64) | 21 | 1.54 (0.96–2.36) | ||||||||
| 18 | 40 (1.7) | 14068 | 7 | 0.50 (0.20–1.03) | 2 | 0.14 (0.02–0.51) | 5 | 0.36 (0.12–0.83) | ||||||||
| 26 | 2 (0.1) | 14330 | 2 | 0.14 (0.02–0.50) | 0 | 0.00 (0.00–0.26) | 2 | 0.14 (0.02–0.50) | ||||||||
| 31 | 43 (1.8) | 13955 | 24 | 1.72 (1.10–2.56) | 7 | 0.50 (0.20–1.03) | 17 | 1.22 (0.71–1.95) | ||||||||
| 33 | 13 (0.6) | 14257 | 5 | 0.35 (0.11–0.82) | 1 | 0.07 (0.00–0.39) | 4 | 0.28 (0.08–0.72) | ||||||||
| 35 | 19 (0.8) | 14225 | 6 | 0.42 (0.15–0.92) | 1 | 0.07 (0.00–0.39) | 5 | 0.35 (0.11–0.82) | ||||||||
| 39 | 50 (2.1) | 13999 | 17 | 1.21 (0.71–1.94) | 3 | 0.21 (0.04–0.63) | 14 | 1.00 (0.55–1.68) | ||||||||
| 45 | 25 (1.1) | 14217 | 12 | 0.84 (0.44–1.47) | 3 | 0.21 (0.04–0.62) | 9 | 0.63 (0.29–1.20) | ||||||||
| 51 | 55 (2.3) | 13943 | 17 | 1.22 (0.71–1.95) | 2 | 0.14 (0.02–0.52) | 15 | 1.08 (0.60–1.77) | ||||||||
| 52 | 83 (3.5) | 13388 | 27 | 2.02 (1.33–2.93) | 5 | 0.37 (0.12–0.87) | 22 | 1.64 (1.03–2.49) | ||||||||
| 53 | 57 (2.4) | 13903 | 22 | 1.58 (0.99–2.40) | 2 | 0.14 (0.02–0.52) | 20 | 1.44 (0.88–2.22) | ||||||||
| 56 | 36 (1.5) | 14043 | 15 | 1.07 (0.60–1.76) | 4 | 0.28 (0.08–0.73) | 11 | 0.78 (0.39–1.40) | ||||||||
| 58 | 44 (1.9) | 13910 | 9 | 0.65 (0.30–1.23) | 4 | 0.29 (0.08–0.74) | 5 | 0.36 (0.12–0.84) | ||||||||
| 59 | 36 (1.5) | 14069 | 15 | 1.07 (0.60–1.76) | 3 | 0.21 (0.04–0.62) | 12 | 0.85 (0.44–1.49) | ||||||||
| 66 | 44 (1.9) | 14062 | 14 | 1.00 (0.54–1.67) | 4 | 0.28 (0.08–0.73) | 10 | 0.71 (0.34–1.31) | ||||||||
| 68 | 23 (1.0) | 14168 | 10 | 0.71 (0.34–1.30) | 5 | 0.35 (0.11–0.82) | 5 | 0.35 (0.11–0.82) | ||||||||
| 70 | 14 (0.6) | 14217 | 3 | 0.21 (0.04–0.62) | 0 | 0.00 (0.00–0.26) | 3 | 0.21 (0.04–0.62) | ||||||||
| 73 | 16 (0.7) | 14245 | 9 | 0.63 (0.29–1.20) | 1 | 0.07 (0.00–0.39) | 8 | 0.56 (0.24–1.11) | ||||||||
| 82 | 14 (0.6) | 14233 | 5 | 0.35 (0.11–0.82) | 1 | 0.07 (0.00–0.39) | 4 | 0.28 (0.08–0.72) | ||||||||
| LR HPV‡‡ | 175 (7.4) | 11893 | 98 | 8.24 (6.69–10.04) | 45 | 3.78 (2.76–5.06) | 84 | 7.06 (5.63–8.74) | ||||||||
| Low risk | ||||||||||||||||
| 6 | 42 (1.8) | 14195 | 14 | 0.99 (0.54–1.65) | 2 | 0.14 (0.02–0.51) | 12 | 0.85 (0.44–1.48) | ||||||||
| 11 | 5 (0.2) | 14293 | 5 | 0.35 (0.11–0.82) | 1 | 0.07 (0.00–0.39) | 4 | 0.28 (0.08–0.72) | ||||||||
| 40 | 4 (0.2) | 14363 | 1 | 0.07 (0.00–0.39) | 0 | 0.00 (0.00–0.26) | 1 | 0.07 (0.00–0.39) | ||||||||
| 42 | 25 (1.1) | 14104 | 15 | 1.06 (0.60–1.75) | 3 | 0.21 (0.04–0.62) | 12 | 0.85 (0.44–1.49) | ||||||||
| 54 | 35 (1.5) | 14098 | 28 | 1.99 (1.32–2.87) | 7 | 0.50 (0.20–1.02) | 21 | 1.49 (0.92–2.28) | ||||||||
| 61 | 38 (1.6) | 13944 | 25 | 1.79 (1.16–2.65) | 7 | 0.50 (0.20–1.03) | 18 | 1.29 (0.77–2.04) | ||||||||
| 72 | 8 (0.3) | 14301 | 3 | 0.21 (0.04–0.61) | 2 | 0.14 (0.02–0.51) | 1 | 0.07 (0.00–0.39) | ||||||||
| 81 | 15 (0.6) | 14183 | 11 | 0.78 (0.39–1.39) | 2 | 0.14 (0.02–0.51) | 9 | 0.63 (0.29–1.20) | ||||||||
| 89 | 40 (1.7) | 13907 | 29 | 2.09 (1.40–2.99) | 4 | 0.29 (0.08–0.74) | 25 | 1.80 (1.16–2.65) | ||||||||
| Undetermined risk | ||||||||||||||||
| 34 | 1 (0.0) | 14358 | 2 | 0.14 (0.02–0.50) | 1 | 0.07 (0.00–0.39) | 1 | 0.07 (0.00–0.39) | ||||||||
| 44 | 17 (0.7) | 14184 | 17 | 1.20 (0.70–1.92) | 3 | 0.21 (0.04–0.62) | 14 | 0.99 (0.54–1.66) | ||||||||
| 62 | 55 (2.3) | 13862 | 25 | 1.80 (1.17–2.66) | 8 | 0.58 (0.25–1.14) | 17 | 1.23 (0.71–1.96) | ||||||||
| 67 | 22 (0.9) | 14224 | 11 | 0.77 (0.39–1.38) | 1 | 0.07 (0.00–0.39) | 10 | 0.70 (0.34–1.29) | ||||||||
| 71 | 6 (0.3) | 14312 | 2 | 0.14 (0.02–0.50) | 1 | 0.07 (0.00–0.39) | 1 | 0.07 (0.00–0.39) | ||||||||
| 83 | 23 (1.0) | 14191 | 12 | 0.85 (0.44–1.48) | 3 | 0.21 (0.04–0.62) | 9 | 0.63 (0.29–1.20) | ||||||||
| 84 | 33 (1.4) | 14063 | 33 | 2.35 (1.62–3.30) | 5 | 0.36 (0.12–0.83) | 28 | 1.99 (1.32–2.88) | ||||||||
| Species§§ | ||||||||||||||||
| 1 | 64 (2.7) | 13672 | 39 | 2.85 (2.03–3.90) | 7 | 0.51 (0.21–1.05) | 32 | 2.34 (1.60–3.30) | ||||||||
| 3 | 152 (6.5) | 12925 | 89 | 6.89 (5.53–8.47) | 27 | 2.09 (1.38–3.04) | 62 | 4.80 (3.68–6.15) | ||||||||
| 5 | 71 (3.0) | 13798 | 23 | 1.67 (1.06–2.50) | 3 | 0.22 (0.04–0.64) | 20 | 1.45 (0.89–2.24) | ||||||||
| 6 | 127 (5.4) | 13376 | 40 | 2.99 (2.14–4.07) | 10 | 0.75 (0.36–1.37) | 30 | 2.24 (1.51–3.20) | ||||||||
| 7 | 168 (7.1) | 13058 | 52 | 3.98 (2.97–5.22) | 14 | 1.07 (0.59–1.80) | 38 | 2.91 (2.06–3.99) | ||||||||
| 9 | 290 (12.3) | 11758 | 63 | 5.36 (4.12–6.86) | 20 | 1.70 (1.04–2.63) | 43 | 3.66 (2.65–4.93) | ||||||||
| 10 | 64 (2.7) | 13947 | 32 | 2.29 (1.57–3.24) | 6 | 0.43 (0.16–0.94) | 26 | 1.86 (1.22–2.73) | ||||||||
| Genotype . | Prevalence at entry, n (%)* . | Woman-months of follow-up† . | All incident infections . | . | No coinfection‡ . | . | One or more coinfection‡ . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | No. incident infections§ . | Incidence rate per 1,000 woman-months (95% CI) . | No. incident infections∥ . | Incidence rate per 1,000 woman-months (95% CI) . | No. incident infections¶ . | Incidence rate per 1,000 woman-months (95% CI) . | ||||||||
| Any HPV** | 603 (25.6) | 9075 | 118 | 13.00 (10.76–15.57) | ||||||||||||
| HR-HPV†† | 493 (20.9) | 10150 | 94 | 9.26 (7.48–11.33) | 45 | 4.43 (3.23–5.93) | 49 | 4.83 (3.57–6.38) | ||||||||
| 16 | 110 (4.7) | 13596 | 24 | 1.77 (1.13–2.63) | 3 | 0.22 (0.05–0.64) | 21 | 1.54 (0.96–2.36) | ||||||||
| 18 | 40 (1.7) | 14068 | 7 | 0.50 (0.20–1.03) | 2 | 0.14 (0.02–0.51) | 5 | 0.36 (0.12–0.83) | ||||||||
| 26 | 2 (0.1) | 14330 | 2 | 0.14 (0.02–0.50) | 0 | 0.00 (0.00–0.26) | 2 | 0.14 (0.02–0.50) | ||||||||
| 31 | 43 (1.8) | 13955 | 24 | 1.72 (1.10–2.56) | 7 | 0.50 (0.20–1.03) | 17 | 1.22 (0.71–1.95) | ||||||||
| 33 | 13 (0.6) | 14257 | 5 | 0.35 (0.11–0.82) | 1 | 0.07 (0.00–0.39) | 4 | 0.28 (0.08–0.72) | ||||||||
| 35 | 19 (0.8) | 14225 | 6 | 0.42 (0.15–0.92) | 1 | 0.07 (0.00–0.39) | 5 | 0.35 (0.11–0.82) | ||||||||
| 39 | 50 (2.1) | 13999 | 17 | 1.21 (0.71–1.94) | 3 | 0.21 (0.04–0.63) | 14 | 1.00 (0.55–1.68) | ||||||||
| 45 | 25 (1.1) | 14217 | 12 | 0.84 (0.44–1.47) | 3 | 0.21 (0.04–0.62) | 9 | 0.63 (0.29–1.20) | ||||||||
| 51 | 55 (2.3) | 13943 | 17 | 1.22 (0.71–1.95) | 2 | 0.14 (0.02–0.52) | 15 | 1.08 (0.60–1.77) | ||||||||
| 52 | 83 (3.5) | 13388 | 27 | 2.02 (1.33–2.93) | 5 | 0.37 (0.12–0.87) | 22 | 1.64 (1.03–2.49) | ||||||||
| 53 | 57 (2.4) | 13903 | 22 | 1.58 (0.99–2.40) | 2 | 0.14 (0.02–0.52) | 20 | 1.44 (0.88–2.22) | ||||||||
| 56 | 36 (1.5) | 14043 | 15 | 1.07 (0.60–1.76) | 4 | 0.28 (0.08–0.73) | 11 | 0.78 (0.39–1.40) | ||||||||
| 58 | 44 (1.9) | 13910 | 9 | 0.65 (0.30–1.23) | 4 | 0.29 (0.08–0.74) | 5 | 0.36 (0.12–0.84) | ||||||||
| 59 | 36 (1.5) | 14069 | 15 | 1.07 (0.60–1.76) | 3 | 0.21 (0.04–0.62) | 12 | 0.85 (0.44–1.49) | ||||||||
| 66 | 44 (1.9) | 14062 | 14 | 1.00 (0.54–1.67) | 4 | 0.28 (0.08–0.73) | 10 | 0.71 (0.34–1.31) | ||||||||
| 68 | 23 (1.0) | 14168 | 10 | 0.71 (0.34–1.30) | 5 | 0.35 (0.11–0.82) | 5 | 0.35 (0.11–0.82) | ||||||||
| 70 | 14 (0.6) | 14217 | 3 | 0.21 (0.04–0.62) | 0 | 0.00 (0.00–0.26) | 3 | 0.21 (0.04–0.62) | ||||||||
| 73 | 16 (0.7) | 14245 | 9 | 0.63 (0.29–1.20) | 1 | 0.07 (0.00–0.39) | 8 | 0.56 (0.24–1.11) | ||||||||
| 82 | 14 (0.6) | 14233 | 5 | 0.35 (0.11–0.82) | 1 | 0.07 (0.00–0.39) | 4 | 0.28 (0.08–0.72) | ||||||||
| LR HPV‡‡ | 175 (7.4) | 11893 | 98 | 8.24 (6.69–10.04) | 45 | 3.78 (2.76–5.06) | 84 | 7.06 (5.63–8.74) | ||||||||
| Low risk | ||||||||||||||||
| 6 | 42 (1.8) | 14195 | 14 | 0.99 (0.54–1.65) | 2 | 0.14 (0.02–0.51) | 12 | 0.85 (0.44–1.48) | ||||||||
| 11 | 5 (0.2) | 14293 | 5 | 0.35 (0.11–0.82) | 1 | 0.07 (0.00–0.39) | 4 | 0.28 (0.08–0.72) | ||||||||
| 40 | 4 (0.2) | 14363 | 1 | 0.07 (0.00–0.39) | 0 | 0.00 (0.00–0.26) | 1 | 0.07 (0.00–0.39) | ||||||||
| 42 | 25 (1.1) | 14104 | 15 | 1.06 (0.60–1.75) | 3 | 0.21 (0.04–0.62) | 12 | 0.85 (0.44–1.49) | ||||||||
| 54 | 35 (1.5) | 14098 | 28 | 1.99 (1.32–2.87) | 7 | 0.50 (0.20–1.02) | 21 | 1.49 (0.92–2.28) | ||||||||
| 61 | 38 (1.6) | 13944 | 25 | 1.79 (1.16–2.65) | 7 | 0.50 (0.20–1.03) | 18 | 1.29 (0.77–2.04) | ||||||||
| 72 | 8 (0.3) | 14301 | 3 | 0.21 (0.04–0.61) | 2 | 0.14 (0.02–0.51) | 1 | 0.07 (0.00–0.39) | ||||||||
| 81 | 15 (0.6) | 14183 | 11 | 0.78 (0.39–1.39) | 2 | 0.14 (0.02–0.51) | 9 | 0.63 (0.29–1.20) | ||||||||
| 89 | 40 (1.7) | 13907 | 29 | 2.09 (1.40–2.99) | 4 | 0.29 (0.08–0.74) | 25 | 1.80 (1.16–2.65) | ||||||||
| Undetermined risk | ||||||||||||||||
| 34 | 1 (0.0) | 14358 | 2 | 0.14 (0.02–0.50) | 1 | 0.07 (0.00–0.39) | 1 | 0.07 (0.00–0.39) | ||||||||
| 44 | 17 (0.7) | 14184 | 17 | 1.20 (0.70–1.92) | 3 | 0.21 (0.04–0.62) | 14 | 0.99 (0.54–1.66) | ||||||||
| 62 | 55 (2.3) | 13862 | 25 | 1.80 (1.17–2.66) | 8 | 0.58 (0.25–1.14) | 17 | 1.23 (0.71–1.96) | ||||||||
| 67 | 22 (0.9) | 14224 | 11 | 0.77 (0.39–1.38) | 1 | 0.07 (0.00–0.39) | 10 | 0.70 (0.34–1.29) | ||||||||
| 71 | 6 (0.3) | 14312 | 2 | 0.14 (0.02–0.50) | 1 | 0.07 (0.00–0.39) | 1 | 0.07 (0.00–0.39) | ||||||||
| 83 | 23 (1.0) | 14191 | 12 | 0.85 (0.44–1.48) | 3 | 0.21 (0.04–0.62) | 9 | 0.63 (0.29–1.20) | ||||||||
| 84 | 33 (1.4) | 14063 | 33 | 2.35 (1.62–3.30) | 5 | 0.36 (0.12–0.83) | 28 | 1.99 (1.32–2.88) | ||||||||
| Species§§ | ||||||||||||||||
| 1 | 64 (2.7) | 13672 | 39 | 2.85 (2.03–3.90) | 7 | 0.51 (0.21–1.05) | 32 | 2.34 (1.60–3.30) | ||||||||
| 3 | 152 (6.5) | 12925 | 89 | 6.89 (5.53–8.47) | 27 | 2.09 (1.38–3.04) | 62 | 4.80 (3.68–6.15) | ||||||||
| 5 | 71 (3.0) | 13798 | 23 | 1.67 (1.06–2.50) | 3 | 0.22 (0.04–0.64) | 20 | 1.45 (0.89–2.24) | ||||||||
| 6 | 127 (5.4) | 13376 | 40 | 2.99 (2.14–4.07) | 10 | 0.75 (0.36–1.37) | 30 | 2.24 (1.51–3.20) | ||||||||
| 7 | 168 (7.1) | 13058 | 52 | 3.98 (2.97–5.22) | 14 | 1.07 (0.59–1.80) | 38 | 2.91 (2.06–3.99) | ||||||||
| 9 | 290 (12.3) | 11758 | 63 | 5.36 (4.12–6.86) | 20 | 1.70 (1.04–2.63) | 43 | 3.66 (2.65–4.93) | ||||||||
| 10 | 64 (2.7) | 13947 | 32 | 2.29 (1.57–3.24) | 6 | 0.43 (0.16–0.94) | 26 | 1.86 (1.22–2.73) | ||||||||
Prevalence among the 2,356 women who completed at least one clinical visit.
Months of follow-up for subjects at risk of acquiring an infection.
Other HPV genotypes detected at time of acquisition of the index infection.
Overall number of genotype-specific incident infections: 476, including HR-HPV, 243 and LR-HPV, 233.
Number of genotype-specific incident infections with no coinfection: 101, including HR-HPV, 51 and LR-HPV, 50.
Number of genotype-specific incident infections with 1+ coinfection: 375, including HR-HPV, 192 and LR-HPV, 183.
Acquisition of any HPV type after an HPV-negative result. For example, if a woman tested positive for HPV-16 at her second clinical visit and for HPV-81 at her third visit, this would not count as an acquisition event for any HPV analysis.
Acquisition of an HR-HPV type after an HR-HPV–negative result. For example, if a woman tested positive for HPV-16 at her second clinical visit and for HPV-18 at her third visit, this would not count as an acquisition event for HR-HPV analysis.
Acquisition of a LR-HPV type after an LR-HPV–negative result. Includes genotypes of undetermined oncogenic risk.
α-Papillomavirus species: species 1 comprises types 42 and 89; species 3 comprises types 61, 62, 72, 81, 83, and 84; species 5 comprises types 26, 51, and 82; species 6 comprises types 53, 56, and 66; species 7 comprises types 18, 39, 45, 59, 68, and 70; species 9 comprises types 16, 31, 33, 35, 52, 58, and 67; and species 10 comprises types 6, 11, and 44.